Did you mean iodide and potassium iodide?
Displaying drugs 12376 - 12400 of 14519 in total
Ladarixin
Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Β-Cell Function).
Investigational
Matched Description: … investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and …
Vafidemstat
Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).
Investigational
Matched Description: … Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary …
Plumbagin
Plumbagin is a compound investigated for its anticancer activity. It has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.
Investigational
Matched Description: … It has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.[A253102] …
Betula pendula tar oil
Betula pendula tar oil is an essential oil found in the buds of the plant with the same name. The origin plant, also known as the European white or silver birch, grows mainly in the northern hemisphere. This oil is usually obtained by using both hydrodistillation and micro-distillation and it...
Nutraceutical
Matched Description: … This oil is usually obtained by using both hydrodistillation and micro-distillation[A33154] and it is ... conformed mainly by [DB11143] and [DB11359]. …
Pranlukast
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Investigational
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Ty800
Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. It is being developed by AVANT Immunotherapeutics, Inc.
Investigational
MVA3000
MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or skin conditions such as eczema.
Investigational
IGN301
IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).
Investigational
ARC183
ARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity and specificity. The key
advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life,...
Investigational
Matched Description: … forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity and ... The key
advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short …
RAV12
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
Investigational
Matched Description: … RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and …
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
QS-21
QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment. It is the leading member of the Stimulon family of adjuvants. As a vaccine additive, it is currently being...
Investigational
Matched Description: … QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies …
IDD-3
IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
Investigational
TA-CIN
TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
Investigational
HSV-2 theracine
HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.
Investigational
Q-Derp1
Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.
Investigational
BI-K0376
BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.
Investigational
Matched Description: … It is under investigation by Pfizer and has gone through phase I of the clinical trails. …
TRX1
TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.
Investigational
HGS-TR2J
HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Investigational
Matched Description: … It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial. …
FAV-201
FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
Investigational
Gavilimomab
Investigational
(2S)-2-(1H-indol-3-yl)hexanoic acid
Experimental
Displaying drugs 12376 - 12400 of 14519 in total